Norgine receives SMC approval from Setofilm

Norgine has announced that its orodispersible film product Setofilm has been accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland.

The therapy is licensed for the prevention and treatment of nausea and vomiting occurring as a postoperative side effect or as a consequence of chemotherapy and radiotherapy. It is Europe's first prescription-only medicine developed as an orodispersible film formulation.

Setofilm dissolves in a few seconds after being placed on the tongue and can be swallowed with saliva without the need for water. This allows it to reduce the pill burden and enables patients to take their medication virtually anywhere.

Bob Cuffe, general manager for the UK and Ireland at Norgine, said this decision represents a recognition of Setofilm's "role in helping both adults and children who are suffering from debilitating side effects, especially following chemotherapy treatment and other very serious conditions".

This comes after the company's drug Targaxan was approved for Scottish NHS use as a treatment for overt hepatic encephalopathy in September 2013.